ClinicalTrials.gg
CompletedNCT07950631Updated Nov 20, 2026

Colistin Use in Neonates ICU Patients With Gram Negative Resistant Infection

An observational study in Sepsis, sponsored by Helwan University. Completed at 1 site in Egypt. Open to participants aged 26 Weeks to 37 Weeks. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Helwan University · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
26 Weeks to 37 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Sepsis with a site in Egypt — 25 open to participants now, 27 under way, 3 of them phase 3. Sepsis · Egypt.

Enrollment
55th of 55
20 · median 80
Started
2024
with 13 others
Observational
55 of 106
14 open now
Registered
106th of 106
by date

Among the 106 studies in Sepsis with a site in Egypt, this one is the 55th largest by enrollment of the 55 observational ones that give a count, is one of 14 that started in 2024, is one of 55 observational ones, and was the 106th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

25 of the 106 studies in Sepsis with a site in Egypt are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 26 Weeks to 37 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Sepsis with a site in Egypt, or all of them as a file.
02

Study summary

Prospective study evaluating the pharmacokinetics of colistin after IV administration of colistin different doses

Read the detailed description

4. Scientific committee approval (Was it scientifically approved by the department?) Yes

Date of approval: 2-7-2024

5. Background and Rationale: (Describe the research question and justification for undertaking the study explaining the aspects of novelty in the study) 3. Background and Rationale: Neonatal bacterial sepsis remains one of the major causes of neonatal morbidity and mortality, especially in hospitalized term and preterm neonates all around the world and especially in low- and middle-income countries. An estimated 1.3 million episodes of neonatal sepsis occur annually with 200,000 sepsis-attributable deaths each year worldwide. ("Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017," 2018) The limited therapeutic options against antimicrobial drug-resistant Gram-negative bacteria have led to the development and study of several novel antibacterial agents including β-lactam/β-lactamase inhibitor combinations (BL-BLIs) and the use of old or repurposed antibiotics. (Chiotos, etal.,2020) Colistin is among the very few agents still effective against carbapenem-resistant Gram-negative bacteria. It has been used clinically since the late 1950s but was substituted some decades later by newer antimicrobials owing to reported neurotoxicity and nephrotoxicity. (Bergen, etal., 2006) colistin is considered to be less nephrotoxic compared to aminoglycosides (Conway et al., 2000). It has been demonstrated that colistin may affect renal function when combined with aminoglycosides but not when used as monotherapy (Al-Aloul et al., 2005). It has been shown that colistin can increase serum creatinine levels, but this renal effect is mild and is not usually associated with severe renal effects. Furthermore, it depends on the duration of treatment, whereas a return to normal creatinine levels is observed within one month of discontinuing treatment (Al-Aloul et al., 2005).

Colistin has been recommended by the Infectious Diseases Society of America (IDSA) 2022 guidance for the treatment of MDR-GN bacteria only as an alternate strategy when first line options are not available or tolerated (mainly combination beta-lactamase inhibitors, carbapenems, or monobactam). (Tamma et al., 2022) In low-middle-income countries (LMICs), colistin is the most prevalent antimicrobial and most studies come from these countries. Because of the concomitant use of other antimicrobials with colistin, the severity of the clinical condition in neonates, the lack of case control studies in neonates and infants, and the retrospective character of the studies reported, it is difficult to draw conclusions on the efficacy and safety of colistin in neonates. Renal impairment and electrolyte deficiencies, such as magnesium and potassium possibly related to renal tubulopathy, have been reported in a review of colistin use in neonates. However, concomitant nephrotoxic agents and clinical comorbidities contribute to nephrotoxicity and renal injury. Moreover, evidence of neurotoxicity related to colistin use is rare in neonates (Nakwan, etal.2019).

The increasing problem of the resistance of microorganisms such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae has led researchers to reapply this old drug, especially in cases where there are no other treatment options due to multi-resistant strains. Even though colistin is considered the last line therapy for these microorganisms, several cases of colistin resistance have emerged, particularly against Pseudomonas aeruginosa. Resistance to the other two pathogens, Acinetobacter baumannii and Klebsiella pneumoniae, is variable. It seems to be increasing, especially for Acinetobacter baumannii, whereas resistance to Klebsiella pneumoniae is relatively rare. This phenomenon has been observed in several cases (Ko et al., 2007). It is suggested that the combination of colistin with other antibiotics can minimize the potential for the emergence of resistance with colistin monotherapy against A. baumannii.

There is a paucity of PK data in pediatrics and neonates due to complicated pharmacokinetics, high interpatient variability, and narrow therapeutic indices. Therefore, recommendations for dosage in neonates are challenging. According to a PK study in neonates with normal renal function, the daily dose of CMS should be >150,000 IU/kg/day to achieve an average steady-state plasma colistin concentration (Css, avg) of >1±0.4 µg/mL, with close monitoring of renal function (Nakwan et al., 2016)

. Current colistin dosing regimens result both in a subtherapeutic peak concentration and a prolonged time to steady state, leading to suboptimal and delayed effective treatment. Therefore, strategies involving higher doses and longer dosing intervals along with loading doses have been proposed, in order to attain more effective killing There is limited data about the systemic colistin use in neonatal population. For this reason, a prospective observational study was planned to evaluate the efficacy and safety of colistin in conventional doses and high doses used to treat multidrug-resistant microorganisms in neonatal intensive care unit settings.

03

Conditions studied

  • Sepsis

Browse trials for

04

Who can participate

Ages eligible
26 Weeks to 37 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Neonates

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Neonates aged between (0-28 days) Preterm infants
  • Critically ill patients with nosocomial infection with proven culture resistant gram-negative bacteria.
  • Neonates who received colistin for at least 4 days.

Exclusion criteria

Exclusion Criteria:

  • - Neonates Serum creatinine ≥1.5 baseline before colistin
  • Neonates Receive colistin before NICU stay
  • Neonates administered concurrent nephrotoxic drugs including amphotericin, gentamicin, amikacin.
  • Patients with major congenital malformation affecting pharmacokinetics of colistin including heart \& renal abnormality were excluded.
  • Patients with elevated serum or alanine aminotransferase or direct of >3mg/dL within the past 24 hours
  • Patients with illness with no expectation of survival.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • Prospective study evaluating the pharmacokinetics of colistin after intravenous administration

    Prospective study evaluating the pharmacokinetics of colistin after intravenous administration of colistimethate sodium (CMS) in the critically ill neonates with Gram-negative bacterial infections and reaching steady state after 4 days (Peak (Cmax) \& trough (Cmin)) comparing two different colistin doses conventional dose 150000 IU/Kg/day divided into three doses and High dose 225000 IU/Kg/day divided into three doses

    Drug: Polymyxin E (Colistin)

Interventions

  • DrugColistinStudies of ColistinColistin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. Evaluation of neonatal efficacy of different administered doses of IV colistin in neonatal sepsis. 2. Assessment of colistin related AKI rates in NICU. 3. Development of personalized approach for dose selection in neonatal sepsis 4. Characterize pharmacokinetics parameters in neonates including volume of distribution \& clearance 5. Correlate the pharmacokinetics parameter with microbiological, clinical response and toxicity

06

What researchers measure

Primary outcomes

  1. 1. Evaluation of neonatal efficacy of different administered doses of IV colistin in neonatal sepsis. 2. Assessment of colistin related AKI rates in NICU. 3. Development of personalized approach for dose selection in neonatal sepsis

    Time frame: 4 days

07

Study locations

1 site
  • Cairo Univrsity Hospitals
    Cairo, 11435, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Mar 2025, 3 months.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's 3 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Dec 16, 2024
Primary completionActual
Mar 16, 2025
CompletionActual
Aug 16, 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950631
Lead sponsor
Helwan University
Responsible party
Mahmoud I Mostafa (Lecturer Clinical pharmacy practice, Helwan University) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 16, 2024
Primary completion
Mar 16, 2025
Completion
Aug 16, 2025
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion